GPCR Therapeutics

South Korean clinical-stage biotech (Seoul) developing novel therapeutics targeting GPCR heteromers in cancer, including GPC-100 + propranolol. Note: primarily an internal drug developer rather than a peptide supplier or CDMO for third-party sourcing.

Directory assessment: GPCR Therapeutics is listed as a supplier in the peptide supply chain, serving Asia markets from South Korea. This supplier operates as a reseller or distributor, sourcing products from verified upstream manufacturers. This profile lists 1 source for reference. This supplier has a lower confidence score — independent verification and third-party testing are strongly recommended before any transaction.